Application of sesquiterpene lactone compound in preparation of medicine for treating liver cancer

The invention discloses application of a sesquiterpene lactone compound in preparation of a medicine for treating liver cancer, and the elephantopus tomentosus monomer EM-6 shown in the formula (I) is a novel sesquiterpene lactone compound extracted and identified from elephantopus tomentosus, and has a good proliferation inhibition effect on liver cancer cells. The toxicity to liver epithelial LO2 cells and bronchial epithelial-like HBE cells is relatively low; on the other hand, the EM-6 can cause S-phase retardation of liver cancer cells Huh-7 and activation of an MAPK pathway through ROS accumulation, and cell apoptosis is induced. In addition, it is found for the first time that when the EM-6 and the BafA1 are combined for use, the curative effect of treating the liver cancer is remarkable, and the application prospect is wide. 申请公开了倍半萜内酯类化合物在制备治疗肝癌药物中的应用，本申请式(I)的白花地胆草单体EM-6是从白花地胆草中的提取鉴定的新型倍半萜内酯类化合物，对肝癌细胞具有较好增殖抑制作用，且对肝上皮LO2细胞以及支气管上皮样HBE细胞具有较低毒性；另一方面，EM-6可以通过ROS积累，造成肝癌细胞Huh-7细胞S期阻滞及激活MAPK通路，诱导细胞凋亡。此外，本申请首